Gastrointestinal Cancer | Topics

Complete Pathological Responses Seen for Resectable HCC Treated With Neoadjuvant Cemiplimab
April 17, 2021

Twenty percent of patients with resectable hepatocellular carcinoma experienced significant tumor necrosis when treated with neoadjuvant cemiplimab-rwlc, according to data from a phase 2a open label.

Addition of Nivolumab Improves OS in Patients with Unresectable, Advanced ESCC
April 08, 2021

The addition of nivolumab to either chemotherapy or ipilimumab improved overall survival among patients with unresectable advanced or metastatic esophageal squamous cell carcinoma, according to data from the phase 3 CheckMate-648 trial.

Futibatinib Earns Breakthrough Therapy Designation for FGFR2+ Cholangiocarcinoma
April 01, 2021

Phase 2 trial data support the FDA breakthrough therapy designation for futibatinib in cholangiocarcinoma tumors positive for FGFR2 gene fusions and rearrangements.